专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050227932A1 Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction 审中-公开
标题翻译：组合治疗涉及MDM2的小分子抑制剂：p53相互作用
公开(公告)号：US20050227932A1
公开(公告)日：2005-10-13
申请号：US11072391
申请日：2005-03-04
申请人： Tianbao Lu , Holly Koblish , Anna Maroney
发明人： Tianbao Lu , Holly Koblish , Anna Maroney
IPC分类号： A61K31/4745 , A61K31/5513 , A61K31/704 , A61K31/7072
CPC分类号： A61K45/06 , A61K31/4745 , A61K31/55 , A61K31/5513 , A61K31/704 , A61K31/7072 , A61K2300/00
摘要： The present invention is directed to a combinational therapy for treating cancer or other cell proliferative diseases. Such a therapy combines the use of radiation therapy or chemotherapy with the use of a small molecule inhibitor of the MDM2: p53 interaction.
摘要翻译：本发明涉及治疗癌症或其他细胞增殖性疾病的组合疗法。这种疗法结合使用放射治疗或化学疗法与使用MDM2：p53相互作用的小分子抑制剂。

2. 发明申请

US20060189511A1 Method for cytoprotection through mdm2 and hdm2 inhibition 审中-公开
标题翻译：通过mdm2和hdm2抑制细胞保护的方法
公开(公告)号：US20060189511A1
公开(公告)日：2006-08-24
申请号：US10514338
申请日：2003-05-13
申请人： Holly Koblish , Carl Manthey , Christopher Molly , Tianbao Lu , Daniel Parks , Louis Lafrance , Karen Milkiewicz , Theodore Carver , Bruce Grasberger
发明人： Holly Koblish , Carl Manthey , Christopher Molly , Tianbao Lu , Daniel Parks , Louis Lafrance , Karen Milkiewicz , Theodore Carver , Bruce Grasberger
IPC分类号： A61K38/17 , A01N1/02
CPC分类号： A61K31/5513
摘要： The present invention is directed to a method of protecting one or more cells from programmed cytotoxic cell death by contacting the cells with a cytoprotective amount of an MDM2 and/or HDM2 inhibitor. The cytoprotective amount of inhibitor is typically used as a pulsed administration. Useful inhibitors include a class of 1,4-benzodiazepines, which act as inhibitors of MDM2-p53 interactions. The method of the invention can be employed as an adjunct to chemotherapy or radiation therapy. In addition, the methods of the invention can be employed to treat a disease or condition that involves excessive cell death.
摘要翻译：本发明涉及通过使细胞与细胞保护剂量的MDM2和/或HDM2抑制剂接触来保护一种或多种细胞免受程序性细胞毒性细胞死亡的方法。抑制剂的细胞保护量通常用作脉冲给药。有用的抑制剂包括一类1,4-苯二氮卓类，其作为MDM2-p53相互作用的抑制剂。本发明的方法可以用作化疗或放射治疗的辅助物质。此外，本发明的方法可用于治疗涉及过度细胞死亡的疾病或病症。

3. 发明授权

US06375944B1 Methods and compositions for enhancing the immunostimulatory effect of interleukin-12 有权
标题翻译：用于增强白细胞介素-12的免疫刺激作用的方法和组合物
公开(公告)号：US06375944B1
公开(公告)日：2002-04-23
申请号：US09395038
申请日：1999-09-13
申请人： Giorgio Trinchieri , William M. F. Lee , Holly Koblish
发明人： Giorgio Trinchieri , William M. F. Lee , Holly Koblish
IPC分类号： A61K3820
CPC分类号： A61K39/39 , A61K38/208 , A61K2039/55511 , A61K2039/55538 , Y02A50/383 , Y02A50/388 , Y02A50/41 , Y02A50/412 , Y02A50/423 , Y02A50/466 , A61K2300/00
摘要： Methods for enhancing the therapeutic and adjuvant use of IL-12 by reducing unwanted transient immunosuppression caused by IL-12 or by high doses thereof involve co-administering IL-12 with an effective amount of an agent that inhibits or neutralizes nitric oxide (NO) in vivo. Enhanced vaccine therapy involves co-administering the IL-12 adjuvant, a selected vaccine antigen and the NO inhibiting/neutralizing agent. Additionally, the toxicity of IL-12 treatment may be reduced by co-administering IL-12 with an effective amount of the NO inhibiting or neutralizing agent. A therapeutic composition characterized by reduced toxicity in mammals contains IL-12, preferably a low dose thereof, and an NO inhibiting or neutralizing agent in a pharmaceutically acceptable carrier. A vaccine composition contains an effective adjuvanting amount of IL-12, an effective amount of an NO inhibiting or neutralizing agent, and an effective protective amount of a vaccine antigen in a pharmaceutically acceptable carrier.
摘要翻译：通过减少由IL-12引起的不需要的瞬时免疫抑制或通过高剂量来增强IL-12的治疗和辅助使用的方法包括将IL-12与有效量的抑制或中和一氧化氮（NO）体内。增强的疫苗疗法包括共同施用IL-12佐剂，选择的疫苗抗原和NO抑制/中和剂。另外，通过与有效量的NO抑制剂或中和剂共同施用IL-12可以降低IL-12治疗的毒性。特征在于哺乳动物毒性降低的治疗组合物含有药物可接受载体中的IL-12，优选低剂量的NO抑制剂或中和剂。疫苗组合物在药学上可接受的载体中含有有效佐剂量的IL-12，有效量的NO抑制剂或中和剂和有效保护量的疫苗抗原。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式